TBWL (Total Body Weight Loss)
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is TBWL (Total Body Weight Loss)?
Total body weight loss: the percentage of starting weight lost, and the primary endpoint modern obesity trials report.
STEP-1: −14.9% on semaglutide 2.4 mg at 68 weeks. SURMOUNT-1: −20.9% on tirzepatide 15 mg at 72 weeks. Reported as a percentage rather than kilograms because 15% means the same metabolic thing whether you started at 100 kg or 200 kg.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where TBWL (Total Body Weight Loss) comes up on this site
On GLP Watchdog, TBWL comes up in 1 research article.
Research that discusses it
Connected terms
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- MASH / MASLD
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- STEP-1 trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers